{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:40:23Z","timestamp":1788579623997,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10549-022-06829-4","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T06:03:58Z","timestamp":1671602638000},"page":"177-181","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genetic testing in privately insured women with surgically treated breast cancer"],"prefix":"10.1007","volume":"198","author":[{"given":"Michaela A.","family":"Dinan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-3492","authenticated-orcid":false,"given":"Sarah","family":"Pitafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Greenup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica B.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary P.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"issue":"2","key":"6829_CR1","first-page":"1986","volume":"17","author":"J Huszno","year":"2019","unstructured":"Huszno J, Ko\u0142osza Z, Grzybowska E (2019) BRCA1 mutation in breast cancer patients: analysis of prognostic factors and survival. Oncol Lett 17(2):1986\u20131995","journal-title":"Oncol Lett"},{"issue":"11","key":"6829_CR2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/jnci\/91.11.943","volume":"91","author":"J Peto","year":"1999","unstructured":"Peto J, Collins N, Barfoot R et al (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91(11):943\u2013949","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"6829_CR3","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1200\/OP.20.00571","volume":"17","author":"J Armstrong","year":"2021","unstructured":"Armstrong J, Lynch K, Virgo KS et al (2021) Utilization, timing, and outcomes of BRCA genetic testing among women with newly diagnosed breast cancer from a national commercially insured population: the ABOARD study. JCO Oncol Pract 17(2):e226\u2013e235","journal-title":"JCO Oncol Pract"},{"key":"6829_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.breast.2021.12.005","volume":"61","author":"D Petrova","year":"2021","unstructured":"Petrova D, Cruz M, S\u00e1nchez MJ (2021) BRCA1\/2 testing for genetic susceptibility to cancer after 25 years: a scoping review and a primer on ethical implications. Breast (Edinburgh, Scotland) 61:66\u201376","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"6829_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejca.2020.12.023","volume":"146","author":"P Pujol","year":"2021","unstructured":"Pujol P, Barberis M, Beer P et al (2021) Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur J Cancer 146:30\u201347","journal-title":"Eur J Cancer"},{"issue":"10","key":"6829_CR6","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1245\/s10434-019-07549-8","volume":"26","author":"ER Manahan","year":"2019","unstructured":"Manahan ER, Kuerer HM, Sebastian M et al (2019) Consensus guidelines on genetic` testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol 26(10):3025\u20133031","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"6829_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41416-018-0127-5","volume":"119","author":"NM Tung","year":"2018","unstructured":"Tung NM, Garber JE (2018) BRCA1\/2 testing: therapeutic implications for breast cancer management. Br J Cancer 119(2):141\u2013152","journal-title":"Br J Cancer"},{"issue":"6","key":"6829_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523\u2013533","journal-title":"N Engl J Med"},{"issue":"1","key":"6829_CR9","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12885-017-3422-2","volume":"17","author":"EM Grindedal","year":"2017","unstructured":"Grindedal EM, Heramb C, Karsrud I et al (2017) Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. BMC Cancer 17(1):438\u2013438","journal-title":"BMC Cancer"},{"issue":"1","key":"6829_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/01.GIM.0000151155.36470.FF","volume":"7","author":"MR McClain","year":"2005","unstructured":"McClain MR, Palomaki GE, Nathanson KL, Haddow JE (2005) Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med 7(1):28\u201333","journal-title":"Genet Med"},{"issue":"6","key":"6829_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18.01631","volume":"37","author":"PD Beitsch","year":"2019","unstructured":"Beitsch PD, Whitworth PW, Hughes K et al (2019) Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol 37(6):453\u2013460","journal-title":"J Clin Oncol"},{"issue":"1","key":"6829_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly MB, Pal T, Berry MP et al (2021) Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compreh Cancer Netw 19(1):77\u2013102","journal-title":"J Natl Compreh Cancer Netw"},{"issue":"15","key":"6829_CR13","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1200\/JCO.18.01854","volume":"37","author":"AW Kurian","year":"2019","unstructured":"Kurian AW, Ward KC, Howlader N et al (2019) Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol 37(15):1305\u20131315","journal-title":"J Clin Oncol"},{"issue":"6 Pt 1","key":"6829_CR14","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1111\/j.1475-6773.2004.00315.x","volume":"39","author":"AB Nattinger","year":"2004","unstructured":"Nattinger AB, Laud PW, Bajorunaite R, Sparapani RA, Freeman JL (2004) An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res 39(6 Pt 1):1733\u20131749","journal-title":"Health Serv Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06829-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06829-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06829-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T05:35:11Z","timestamp":1674797711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06829-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["6829"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06829-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,21]]},"assertion":[{"value":"3 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author Cary Gross has received research funding from the\u00a0NCCN Foundation (Astra-Zeneca) and Genentech, as well as funding from\u00a0Johnson and Johnson to help devise and implement new approaches to sharing clinical trial data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}